Analysis of computed tomography density of liver before and after amiodarone administration

  • Masazumi Matsuda
  • Aoi Otaka
  • Tomoki Tozawa
  • Tomoyuki Asano
  • Koichi Ishiyama
  • Manabu Hashimoto
Original Article

Abstract

Purpose

To evaluate CT density of liver changes between before and after amiodarone administration.

Materials and methods

Twenty-five patients underwent non-enhanced CT including the liver before and after amiodarone administration. We set regions of interest (ROIs) at liver S8, spleen, paraspinal muscle, and calculated average CT density in these ROIs, then compared CT density between liver and other organs. Statistical differences between CT density of liver and various ratios before and after administration were determined, along with correlations between cumulative dose of amiodarone and liver density after administration, density change of liver, and various ratios after administration.

Results

Liver density, liver-to-spleen ratio, and liver-to-paraspinal muscle ratio differed significantly between before and after amiodarone administration. No significant correlations were found between cumulative doses of amiodarone and any of liver density after administration, density change of liver, or various ratios after administration.

Conclusion

CT density of liver after amiodarone administration was significantly higher than that before administration. No correlations were identified between cumulative dose of amiodarone and either liver density after administration or density change of liver. Amiodarone usage should be checked when radiologists identify high density of the liver on CT.

Keywords

Computed tomography Amiodarone CT density of liver 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical statement

This study was approved by the clinical ethics committee of Akita University.

References

  1. 1.
    Nasir H, Anirban B, Suartcha P. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013.  https://doi.org/10.1155/2013/617943.Google Scholar
  2. 2.
    Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160:1741–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101:462–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Kojima S, Kojima S, Ueno H, Takeya M, Ogawa H. Increased density of the liver and amiodarone-associated phospholipidosis. Cardiol Res Pract. 2009.  https://doi.org/10.4061/2009/598940.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med. 1987;147:881–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Goldman IS, Winkler ML, Raper SE, Barker ME, Keung E, Goldberg HI, et al. Increased hepatic density and phospholipidosis due to amiodarone. AJR Am J Roentgenol. 1985;144:541–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Shenasa M, Vaisman U, Wojciechowski M, Denker S, Murthy V, Akhtar M. Abnormal abdominal computerized tomography with amiodarone therapy and clinical significance. Am Heart J. 1984;107:929–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Patrick D, White FE, Adams PC. Long-term amiodarone therapy: a cause of increased hepatic attenuation on CT. Br J Radiol. 1984;57:573–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Markos J, Veronese ME, Nicholson MR, McLean S, Shevland JE. Value of hepatic computerized tomographic scanning during amiodarone therapy. Am J Cardiol. 1985;56:89–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Hirakawa K, Abe K, Ayabe Y, Nishimura M. Analysis of increased hepatic density during chronic amiodarone therapy. Nihon Igaku Hoshasen Gakkai Zasshi. 2003;63:221–4.PubMedGoogle Scholar
  13. 13.
    Singh BN, Cho YW, Kuemmerle HP. Clinical pharmacology of antiarrhythmic drugs: a review and overview, part II. Int J Clin Pharmacol Ther Toxicol. 1981;19:185–99.PubMedGoogle Scholar
  14. 14.
    Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, et al. Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. Drug Des Dev Ther. 2017;11:1827–37.CrossRefGoogle Scholar
  15. 15.
    Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology. 1984;86:926–36.PubMedGoogle Scholar
  16. 16.
    Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC, McCallum RW. Amiodarone-induced liver toxicity. Ann Intern Med. 1988;109:838–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2003;7:435–51.CrossRefPubMedGoogle Scholar
  18. 18.
    Ishida S, Sugino M, Hosokawa T, Sato T, Furutama D, Fukuda A, et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol. 2010;29:84–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Oikawa H, Maesawa C, Sato R, Oikawa K, Yamada H, Oriso S, et al. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J Gastroenterol. 2005;11:5394–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am J Med Sci. 2005;330:257–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR. 1995;16:16–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Murakami T, Baron RL, Peterson MS. Liver necrosis and regeneration after fulminant hepatitis: pathologic correlation with CT and MR findings. Radiology. 1996;198:239–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Heye T, Nelson RC, Ho LM, Marin D, Boll DT. Dual-energy CT applications in the abdomen. AJR Am J Roentgenol. 2012;199:S64–70.CrossRefPubMedGoogle Scholar

Copyright information

© Japan Radiological Society 2018

Authors and Affiliations

  • Masazumi Matsuda
    • 1
  • Aoi Otaka
    • 1
  • Tomoki Tozawa
    • 1
  • Tomoyuki Asano
    • 1
  • Koichi Ishiyama
    • 1
  • Manabu Hashimoto
    • 1
  1. 1.Department of RadiologyAkita University Graduate School of MedicineAkitaJapan

Personalised recommendations